Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.46 |
| ▸ | CHRNG | P07510 | 1/20 | 0.46 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.46 |
| ▸ | CHRND | Q07001 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29990646 | 1.00 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNB4CHRNA3HRH3 | |
| SCHEMBL29960041 | 0.92 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3HRH3 | |
| SCHEMBL20038455 | 0.83 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3895823 | 0.80 | CHKA (0.53) | HRH3 | |
| SCHEMBL1443382 | 0.79 | MBTD1 (0.52) | CHRNB2CHRNA4CHRNA3GPR119CHRNA7 | |
| SCHEMBL15859870 | 0.78 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3HRH3 | |
| SCHEMBL2687257 | 0.78 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3HRH3 | |
| SCHEMBL31329775 | 0.78 | HRH3 (0.57) | CHRNB2CHRNA4CHRNB4CHRNA3HRH3 | |
| SCHEMBL4760567 | 0.78 | HRH3 (0.57) | CHRNB2CHRNA4CHRNB4CHRNA3HRH3 | |
| SCHEMBL20388854 | 0.78 | HRH3 (0.57) | CHRNB2CHRNA4CHRNB4CHRNA3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| CN-117916231-A | Compounds for inhibiting or degrading target proteins, compositions comprising the same, methods of making and methods of using the same | 纽力克斯治疗公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117693502-A | Compounds for inhibiting or degrading ITK, compositions comprising the same, methods of making the same, and methods of using the same | 纽力克斯治疗公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2022235715-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | ITK, NFATC1, TNIK | CHRNB2 4556/4885CHRNA4 4874/4885CHRNB4 4842/4885 |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | MDM2, XIAP, ADRM1 | CHRNB2 4318/4885CHRNA4 4798/4885CHRNB4 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.